A Ret. a saját tőke az Lucid, Inc. - N/A
A saját tőke megtérülése egy vállalkozás nyereségességének mértéke a részvényes saját tőkéjének könyv szerinti értékéhez viszonyítva. Ezt úgy számítják ki, hogy a pénzügyi év nettó eredményét a teljes részvényes tőkével osztják el.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides VivaScope 1500, a reflectance confocal imaging system that enables clinicians and researchers to capture confocal images that depict cellular structures of living tissue; and VivaScope 3000, a hand-held in vivo reflectance confocal microscope for skin imaging. It also offers VivaScan software to schedule patients for examinations, perform imaging examinations on one or more lesions during a visit, review, and report on images obtained during an examination, as well as VivaNet, a digital telepathology system. The company was formerly known as Lucid, Inc. and changed its name to Caliber Imaging & Diagnostics, Inc. in August 2012. Caliber Imaging & Diagnostics, Inc. was founded in 1991 and is headquartered in Andover, Massachusetts.